Clinical presentation, associated factors, and course of cutaneous reaction after the booster dose of COVID-19 vaccination
Issued Date
2024-10-01
Resource Type
ISSN
22873651
eISSN
2287366X
Scopus ID
2-s2.0-85209678884
Journal Title
Clinical and Experimental Vaccine Research
Volume
13
Issue
4
Start Page
309
End Page
314
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical and Experimental Vaccine Research Vol.13 No.4 (2024) , 309-314
Suggested Citation
Jirawattanadon P., Leeyaphan C., Koomanachai P., Pudchakan P., Bunyaratavej S., Kulthanan K., Tuchinda P., Hutachoke T., Nanchaipruek Y., Phumariyapong P. Clinical presentation, associated factors, and course of cutaneous reaction after the booster dose of COVID-19 vaccination. Clinical and Experimental Vaccine Research Vol.13 No.4 (2024) , 309-314. 314. doi:10.7774/cevr.2024.13.4.309 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/102177
Title
Clinical presentation, associated factors, and course of cutaneous reaction after the booster dose of COVID-19 vaccination
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Purpose: A booster coronavirus disease 2019 (COVID-19) vaccination was proposed to pre-serve immunity and prevent new variants of the severe acute respiratory syndrome corona-virus 2 virus. The objectives of this study are to investigate clinical manifestations, associated factors and course of cutaneous reactions after the booster dose of COVID-19 vaccination, compared to the recommended 1st and 2nd doses. Materials and Methods: This retrospective cohort study was conducted at Siriraj Hospital, Bangkok. Adult patients who reported cutaneous reactions after COVID-19 vaccination from April 2021 to February 2022 were included. Data were collected from electronic medical re-cords and analyzed. Results: A total of 521 subjects with a median age of 38 years were included. Females pre-dominated (80.2%). Most reactions were reported after receiving CoronaVac (49.1%) and ChAdOx1 nCoV-19 (46.3%). The injection site reaction was the most reported. Twenty-one patients reported rash after the 3rd booster dose, with messenger RNA vaccines in most cases. Patients in this group had significantly fewer injection site reactions compared to those with the 1st and 2nd vaccination (70.6% vs. 91.5%) with an increasing proportion of new-onset urticaria (17.6% vs. 5.4%, p=0.023). The rash after the 3rd booster vaccination tended to have a longer duration of reactions (p=0.001). Boosting with a vaccine different from the 1st dose may not affect the reaction. Age and sex did not affect booster rash. In this study, no serious cutaneous reactions were found. Conclusion: Most adverse cutaneous reactions after COVID-19 vaccination are mild in sever-ity, especially after booster vaccination, and should not discourage the benefits of getting vac-cinated.